Abstract
Hodgkin lymphoma (HL) patients failing after high dose chemotherapy (HDC) and auto-SCT have a poor outcome. Some patients may still benefit from further treatments. From 1996 to 2016, 137 HL patients (39.5%) out of 347 transplanted experienced post auto-SCT failure. Males/female 61%:39%, median age at auto-SCT 23.4 years and median follow-up 55.6 months (9-153). Type of failure was progressive (46%), relapsed (35%) or persistent disease/refractory disease (19%). Median overall survival (OS) from the time of failure is 20 months; 35 patients (25.5%) are alive. One hundred and four patients received treatment; the response rate was 45%; complete remission in 41 (30%) and partial remission in 21 (15%) patients. 1st interventions post auto-SCT were chemotherapy (39%), radiation therapy (35%) or best supportive care (24%). Twenty-seven patients with 2nd-SCT (allogeneic (15), auto-SCT (2)) and/or brentuximab (18 patients) had superior OS (50.6 months) vs other treatments (22.5 months, P value 0.037). COX regression multivariate analysis identified post auto-SCT treatment failure before 12 months (hazard ratio (HR) 3.37, CI 1.7-6.6, P value < 0.001), presence of B symptoms (HR 2.55, CI 1.4-4.6, P value 0.002), stages III-IV (HR 2.7, C...Continue Reading
References
Apr 24, 1993·Lancet·D C LinchG V Hudson
Nov 20, 1998·The New England Journal of Medicine·D Hasenclever, V Diehl
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M AndréC Gisselbrecht
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Apr 15, 2003·Bone Marrow Transplantation·O PaltielE Naparstek
Mar 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SuredaUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group
Jan 10, 2006·Bone Marrow Transplantation·S AkhtarI Maghfoor
Jan 19, 2007·Haematologica·Armando SantoroMonica Balzarotti
Dec 17, 2008·Hematology·Michael Crump
May 15, 2009·British Journal of Haematology·Alison J MoskowitzCraig H Moskowitz
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Panayotis KaloyannidisAchilles Anagnostopoulos
Aug 30, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sarah F KellerJonathan W Friedberg
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
May 29, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MartínezUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto d
Jun 12, 2013·Bone Marrow Transplantation·S AkhtarI Maghfoor
Oct 8, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnParameswaran N Hari
Jan 21, 2014·Bone Marrow Transplantation·M A Kharfan-DabajaB N Savani
Nov 29, 2014·Medical Oncology·Muhammad Shahzad RaufSaad Akhtar
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Mar 23, 2015·Lancet·Craig H MoskowitzUNKNOWN AETHERA Study Group
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandCraig H Moskowitz
Jul 20, 2016·Blood·Robert ChenAnas Younes
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ChenUNKNOWN KEYNOTE-087
May 18, 2017·American Journal of Hematology·Steven M BairJakub Svoboda
Jun 7, 2017·Leukemia & Lymphoma·Ashish GautamDirk Huebner
Jun 24, 2017·Cancer·Lucy HuiScott F Huntington
Oct 19, 2017·Leukemia & Lymphoma·Erin A ZagadailovTim Illidge